Last spring, a 46-year-old nurse practitioner named Rachel in Tampa told me she'd been prescribing AOD 9604 for about eight months before switching several of her patients to Tesamorelin. "The AOD patients were losing maybe two, three pounds over a couple months. The Tesamorelin patients were coming back with CT scans showing real visceral fat reduction, 15 to 18 percent in some cases. But they were also paying four times as much and dealing with joint pain." She paused. "So neither one is the slam dunk. It depends on what you're optimizing for."
That tension is the whole story with these two peptides. They both target fat. They do it through completely different doors. And the gap between them in terms of evidence, cost, and side effects is wide enough that picking one without understanding the other is a mistake.
Two Completely Different Mechanisms
AOD 9604 is a 16 amino acid fragment snipped from the tail end of human growth hormone (residues 176 to 191), with a tyrosine tacked onto the N-terminus for stability. Here's the thing: it doesn't bind the growth hormone receptor in any meaningful way. The proposed action is through beta-3 adrenergic receptor activation on fat cells, basically a direct lipolytic signal that tells adipocytes to release stored fat. No GH receptor involvement means no IGF-1 bump, no insulin disruption, no broader endocrine ripple.
Tesamorelin works upstream. It's a 44 amino acid GHRH analog with a trans-3-hexenoyl modification that slows breakdown by the enzyme DPP-4. When it hits pituitary somatotrophs, it tells them to release more of the body's own growth hormone. The fat loss you get from Tesamorelin is downstream of GH and IGF-1 elevation. In other words, it's not touching fat cells directly. It's turning up the whole growth hormone axis and letting the cascade do its work.
Think of it like this: AOD 9604 is a flashlight aimed at one wall. Tesamorelin flips on the overhead lights.
What the Clinical Data Actually Shows
This is where the conversation gets honest, and a little uncomfortable for AOD 9604 advocates.
The central human evidence for AOD 9604 is a Phase 2b trial run by Metabolic Pharmaceuticals in 2007. It enrolled 534 obese participants and tested oral AOD 9604 at multiple doses over 12 weeks. The 1 mg dose arm hit statistical significance for weight loss versus placebo, but the effect was modest. Higher doses didn't produce proportionally better results. The original sponsor walked away from Phase 3 development. That's the entire clinical story for this peptide in humans.
Tesamorelin sits in a different category. It has FDA approval (branded as Egrifta) for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. The approval trials measured visceral adipose tissue via CT and MRI imaging and showed clinically significant reductions that meaningfully exceeded placebo. The effect sizes substantially outpaced anything seen in the AOD 9604 trial.
Off-label use of Tesamorelin in non-HIV populations with visceral adiposity has a thinner evidence base, but the mechanistic logic carries over cleanly. You're still stimulating GH release; you're still getting IGF-1 elevation; the downstream fat-mobilization pathway is the same regardless of HIV status.
The boring truth: one of these peptides has FDA-stamped evidence and the other had its development abandoned after Phase 2b. That doesn't mean AOD 9604 is useless. It means the evidence gap is real and patients should know it.
Effect Size, Side Effects, and the Tradeoff
The effect magnitude difference between these two is not subtle. Tesamorelin trials showed meaningful visceral fat reduction on imaging. AOD 9604 showed modest weight loss on a scale. These are different endpoints measured differently, which makes direct comparison imperfect, but the clinical impression is clear: Tesamorelin moves the needle more.
Not sure which GLP-1 is right for you?
Take a 2-minute assessment and get a personalized recommendation after licensed provider review.
Take the Assessment →But Tesamorelin's advantages come with luggage. Because it activates the GH axis, you get the side effects that come with GH axis activation: injection site reactions (the most common), arthralgias, peripheral edema, and in some patients, measurable effects on glucose handling. The Phase 2b trial for AOD 9604, by contrast, reported tolerability essentially comparable to placebo, with no significant changes in glucose, insulin, or IGF-1.
So you're looking at a classic pharmacological tradeoff. More effect, more side effects. Less effect, cleaner tolerability. The IGF-1 elevation from Tesamorelin is worth its own conversation, particularly for patients with a personal or family history of conditions where elevated IGF-1 raises concern. AOD 9604 doesn't touch IGF-1. That's not a minor point.
Dosing and Cost: The Practical Divide
AOD 9604 is typically dosed at 250 to 500 mcg subcutaneous daily, usually in the morning on an empty stomach. Tesamorelin's FDA-approved dose is 2 mg subcutaneous daily; off-label compounding doses tend to range from 1 to 2 mg daily.
The cost gap is significant. AOD 9604 is one of the more affordable compounded peptides per dose. Tesamorelin is substantially more expensive. Branded Egrifta runs several thousand dollars a month. Compounded Tesamorelin brings that down, but it's still typically multiple times the cost of AOD 9604. For patients on long-term fat loss protocols, that monthly difference compounds quickly.
Who Should Consider Which
AOD 9604 makes more sense when:
- Avoiding IGF-1 elevation is a priority (patients with contraindications or risk factors related to elevated IGF-1)
- Cost is a significant constraint
- Goals are incremental, meaning a patient wants mild lipolytic support alongside diet, exercise, and possibly other interventions
- Glucose handling is already borderline, since AOD 9604 doesn't produce GH-mediated insulin effects
Tesamorelin makes more sense when:
- Visceral adiposity is the specific target (the strongest evidence lives here)
- The patient has HIV-associated lipodystrophy (the FDA-approved indication)
- Larger effect magnitude is the priority, and the patient accepts the cost and side effect profile
- The patient has no contraindications to GH axis activation and IGF-1 elevation
Some prescribers combine AOD 9604 with a GH-releasing peptide like Tesamorelin or Sermorelin. The rationale: the GHRH analog stimulates broad, physiological GH release while AOD 9604 layers on targeted lipolytic signaling. It's a reasonable hypothesis. It also has zero formal study behind it, so it remains a clinical judgment call rather than an evidence-based recommendation.
My Honest Take
If I had to pick one thing most people get wrong about this comparison, it's treating these two peptides as interchangeable options at different price points. They're not. AOD 9604 is a GH fragment with a narrow, direct mechanism and modest clinical data. Tesamorelin is a GHRH analog with FDA approval, meaningful visceral fat reduction data, and a full GH-axis side effect profile. Comparing them is a bit like comparing ibuprofen to a corticosteroid injection. Both address inflammation. The scope and consequence are very different.
The right choice depends on the patient's risk profile, their budget, their specific fat distribution, and frankly, their tolerance for ambiguity in the evidence. Patients who want the strongest evidence and the biggest effect will lean toward Tesamorelin. Patients who want a gentler, cheaper, GH-sparing option will lean toward AOD 9604. Neither choice is wrong if it's made with eyes open.
Frequently Asked Questions
Which peptide produces better weight loss results?
Tesamorelin produces larger magnitude effects on visceral adiposity in the available evidence. AOD 9604 produces modest weight loss without GH axis effects. The right choice depends on goals, budget, and willingness to accept GH-related side effects.
Which is FDA approved?
Tesamorelin is FDA approved as Egrifta for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. AOD 9604 is not FDA approved for any indication.
Which has more side effects?
Tesamorelin. Its GH axis activation produces a more pronounced side effect profile including possible glucose effects, edema, and arthralgias. AOD 9604's tolerability profile in the Phase 2b trial was comparable to placebo.
Can I take both at the same time?
Some clinical protocols describe the combination. It has not been formally studied and remains a prescriber decision.
Why is Tesamorelin so much more expensive?
Tesamorelin has an FDA-approved branded product (Egrifta), a more complex 44 amino acid molecular structure, and higher manufacturing costs. Compounded versions are less expensive than branded but still typically cost several times more per month than AOD 9604.
Does AOD 9604 raise IGF-1 levels?
No. The Phase 2b trial directly measured IGF-1 and found no significant change from placebo. This is one of AOD 9604's key differentiators from Tesamorelin.
Is there evidence for using these peptides outside of HIV lipodystrophy?
Tesamorelin's strongest evidence is in HIV lipodystrophy. Off-label use for general visceral adiposity is mechanistically supported but has a thinner evidence base. AOD 9604's only major clinical trial was conducted in an obese, non-HIV population, though the results were modest and the program was discontinued.
Compliance Footer
AOD 9604 is not approved by the FDA for any indication. Tesamorelin is FDA approved for reduction of excess abdominal fat in HIV infected patients with lipodystrophy and is not approved for other indications. Compounded versions of both peptides are prepared by licensed compounding pharmacies for individual patients under a valid prescription from a licensed prescriber. Information on this page is educational and is not medical advice. Individual results vary.